1 – 10 of 166
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Prostate-specific antigen bounce after prostate ultra-hypofractionation: associations with 5-year outcomes in the phase 3 trial HYPO-RT-PC
(
- Contribution to journal › Published meeting abstract
-
Mark
Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials
2025) 12th Øresund Workshop on Radiotherapy(
- Contribution to conference › Abstract
-
Mark
Short-term outcomes from the 'Watch and Wait' (WoW) study : prospective cohort study
(
- Contribution to journal › Article
-
Mark
Postoperative leukopenia after cytoreductive surgery and hypertherm intraperitoneal chemotherapy for colorectal carcinomatosis- causes and implication on outcomes in a population-based study
(
- Contribution to journal › Article
-
Mark
Alternative Complement Pathway in Carotid Atherosclerosis : Low Plasma Properdin Levels Associate With Long-Term Cardiovascular Mortality
(
- Contribution to journal › Article
- 2024
-
Mark
Causal discovery in a complex industrial system : A time series benchmark
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Ultrahypofractionated Radiation Therapy for Prostate Cancer Including Seminal Vesicles in the Target Volume : A Treatment-planning Study Based on the HYPO-RT-PC Fractionation Schedule
(
- Contribution to journal › Article
-
Mark
Dose-volume relationships of planned versus estimated delivered radiation doses to pelvic organs at risk and side effects in patients treated with salvage radiotherapy for recurrent prostate cancer
(
- Contribution to journal › Article
-
Mark
Register data on long-term morbidity after prostate ultra-hypofractionation in the HYPO-RT-PC trial
(
- Contribution to journal › Published meeting abstract
-
Mark
Register data on long-term morbidity after prostate cancer radiotherapy with ultra-hypofractionated (2.5 weeks) vs conventional (8 weeks) treatment schedules
2024) U21 Health Sciences Group 2024 Doctoral Student Forum(
- Contribution to conference › Poster